As hospitals look for ways to improve patient satisfaction and boost their Medicare reimbursement, a Henry Ford Hospital study found that an inpatient pharmacist-directed anticoagulation service might be an unexpected opportunity.
[More]
A new Canadian study shows that operating without interrupting warfarin treatment at the time of cardiac device surgery is safe and markedly reduces the incidence of clinically significant hematomas compared to the current standard of care.
[More]
The U.S. Food and Drug Administration today approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist anticoagulation in adults with acute major bleeding.
[More]
The U.S. Food and Drug Administration has accepted Octapharma USA's Biological License Application for octaplex.
[More]
A practical guide on the use of the new oral anticoagulants has been produced by the European Heart Rhythm Association of the European Society of Cardiology.
[More]
Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.
[More]
Despite concerns that have been expressed about possible health risks from high intake of vitamin E, a new review concludes that biological mechanisms exist to routinely eliminate excess levels of the vitamin, and they make it almost impossible to take a harmful amount.
[More]
A study led by researchers at the University of North Carolina indicates that a newly approved blood thinner that blocks a key component of the human blood clotting system may increase the risk and severity of certain viral infections, including flu and myocarditis, a viral infection of the heart and a significant cause of sudden death in children and young adults.
[More]
An evaluation of practice patterns in California hospitals showed a large variation in the use of metal devices called inferior vena cava filters, or VCFs, despite little evidence of their safety and effectiveness.
[More]
Transfusion of donated blood more than three weeks old results in impaired blood vessel function, a new study of hospital patients shows.
[More]
Armetheon, Inc., a clinical stage biopharmaceutical company, announced today that it plans to develop its novel oral anti-coagulant (OAC), tecarfarin (ATI-5923), for a patient population which includes those who have prosthetic heart valves or chronic renal dysfunction.
[More]
Publication of the WOEST trial results reaffirm the study’s major finding that antiplatelet therapy with clopidogrel alone is preferable to the use of both aspirin and clopidogrel in patients undergoing percutaneous coronary intervention who are receiving oral anticoagulant therapy.
[More]
New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).
[More]
rEVO Biologics announced today the results of a major retrospective study analysis of its pivotal phase 3 studies which demonstrate that pregnant patients with hereditary antithrombin deficiency (HD) benefit from ATryn Antithrombin (Recombinant) therapy to prevent venous thromboembolic events (VTE).
[More]
The benefits of extended prophylactic anticoagulation with rivaroxaban in acutely ill hospital patients are outweighed by an increased bleeding risk, shows a study in The New England Journal of Medicine.
[More]
Bed bugs are on the rise and $1,000 per day ordinances are being suggested in cities like Chicago to enforce combat of the pests. "Know thy enemy," says Jorge Parada, MD, medical director, infection control, Loyola University Health System. "There are lots of myths out there about bed bugs and people may be getting caught up over nothing."
[More]
Dilaforette, a Karolinska Development portfolio company, today announces that the company has approval from the regulatory authority in India to start a Phase II study with sevuparin in patients with moderate to severe malaria.
[More]
Researchers have developed a risk-scoring system to identify noncritically ill hospital patients most likely to benefit from prophylactic acid-suppressive medication.
[More]
Critically ill patients in hospital intensive care units (ICUs) are routinely prescribed acid-suppressive medications to reduce their risk of developing stress ulcers and gastrointestinal bleeding, both of which can result from being in a stressful environment and from being intubated. Over the years, this routine practice has often been extended to patients outside the ICU, despite a lack of evidence that this population is at significant risk of these complications.
[More]
Researchers at the Hebrew University of Jerusalem, in collaboration with researchers at the Salk Institute in California, have found for the first time that a specific protein is essential not only for maintaining a healthy retina in the eye, but also may have implications for understanding and possibly treating other conditions in the immune, reproductive, vascular and nervous systems, as well as in various cancers.
[More]